Advice

following an abbreviated submission:

tiotropium (Spiriva® Respimat®) is accepted for use within NHSScotland.

Indication under review: as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.

Tiotropium has previously been accepted for use in adult patients with asthma as add-on maintenance bronchodilator treatment.

Download detailed advice358KB (PDF)

Download

Medicine details

Medicine name:
tiotropium (Spiriva Respimat)
SMC ID:
SMC2118
Indication:
As add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
Pharmaceutical company
Boehringer Ingelheim Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated submission
Status
Accepted
Date advice published:
14 January 2019